)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
NovaBridge Biosciences (NBP) investor relations material
NovaBridge Biosciences Investor Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor Update summary16 Oct, 2025
Business transformation and strategic rebranding
Transitioning to a global biotech platform, leveraging operations in China, the U.S., and Asia for innovation and clinical development, with a focus on business development and translational clinical development.
Adopting a hub-and-spoke model (NovaBridge) to bridge Asian biotech innovation with global markets, creating specialized subsidiaries for focused asset development and risk management.
Emphasizing capital efficiency, rapid proof-of-concept development, and value creation through early clinical validation, strategic exits, or spin-offs.
Pursuing a dual listing on NASDAQ and Hong Kong Stock Exchange to broaden investor base and enhance capital access, supported by a strong balance sheet and private equity backing.
Intending to rebrand as NovaBridge Biosciences, pending shareholder approval at the EGM on October 24, 2025.
Pipeline and clinical assets
Lead asset Givastomig (Claudin 18.2/4-1BB bispecific) shows robust efficacy and safety in gastric cancer, advancing to a global Phase 2 study in Q1 2026, with significant commercial potential.
VIS-101, a bifunctional biologic for wet AMD and DME, acquired for $37M, to be managed by new subsidiary Visara, with global rights and promising phase II data.
Additional pipeline includes Ragistomig, uliledlimab, a 4-1BB/PDL1 bispecific, and a CD73 antibody in phase II, all targeting high unmet needs in oncology, with key data readouts expected in 2026.
Systematic asset screening with over 550 opportunities identified year-to-date, aiming to add 2–4 new molecules annually.
Business development and financial strategy
Focus on in-licensing clinical-stage assets, advancing them to POC within 2–3 years, and monetizing through licensing, spin-offs, or continued development based on asset potential.
Flexible deal structures include upfront payments, equity, milestone fees, and profit sharing, tailored to asset and partner needs.
Hub-and-spoke model enables rapid asset development and de-risked, faster capital payback compared to traditional biotech models.
Pace and scope of new asset additions?
Explain value creation and exit strategy for assets.
Commitment to existing pipeline assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next NovaBridge Biosciences earnings date
Q3 202513 Nov, 2025
Next NovaBridge Biosciences earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of innovative biologics, particularly in the fields of immuno-oncology and immuno-inflammation. The company has a diverse pipeline, including several antibody-based therapies aimed at treating various forms of cancer. These include drugs in different phases of clinical trials, such as Uliledlimab for solid tumors and Lemzoparlimab for hematologic malignancies. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage